© Copyright - Neuro-Sys 2023-2024
© Copyright - Neuro-Sys 2022-2024
© Copyright - Neuro-Sys 2022-2024
© Copyright - Neuro-Sys 2023-2024
Your R&D
department
%20Glass%20Trophy%20.png)
Experts in
neurodegenerative
preclinical modelling
services
40%
of PhDs
240+ studies
in 2024
80%
of bespoke models
10700 sq ft
of labs
70+
posters & publications
Latest
news
POSTERS April 10, 2025
Poster presentation @Synuclein Meeting 2024
"Alpha-synuclein preformed fibrils induce synaptic abnormalities and mitochondrial dysfunction prior any neuronal death"
Poster # N6P51
> More
POSTERS April 2, 2025
Poster presentations @ADPD2025
"Early Synaptic Dysfunction induced by alpha-Synuclein and Amyloid-beta trigger Neurodegeneration in Proteinopathy"
Poster # N6P49
"The Aging Brain: fertile soil for Aβ Toxicity to seed Alzheimer’s Disease"
Poster # N6P50
> More
AWARDS December, 2024
🌟Neuro-Sys Honored with "Best Neurodegenerative Disease CRO 2024" Award! by Global Health Pharma🌟
We are proud to announce that Neuro-Sys has been awarded the prestigious title of "Best Neurodegenerative Disease CRO 2024"! 🏆
This recognition is the result of the hard work and dedication of our talented team, who strive every day to deliver the highest quality studies in neurodegenerative disease research.
We would like to extend our heartfelt gratitude to each of our team members for their expertise, passion, and commitment. A special thanks to our clients for their trust and collaboration. It's because of you that we can continue to push the boundaries of research.
This award is not just an achievement; it is a springboard for new challenges and opportunities. We look forward to continuing our mission and reaching new heights together!
EVENT September, 2024: 🚀 Neuro-Sys Takes Flight: Unveiling Our Cutting-Edge Research Hub!
We are thrilled to announce a transformative milestone in Neuro-Sys' journey! We've moved into our new state-of-the-art facility, spanning an impressive 2,000 m² (approx. 20,000 sq ft). This expansion marks a quantum leap in our capabilities to drive innovation in neurodegenerative research.
Key highlights of our expansion:
-
4x larger space, enabling simultaneous complex studies
-
A talented, specialized team of 40+ experts
-
Massive investment in cutting-edge equipment
-
Enhanced capacity for more robust and relevant studies
This move empowers us to deliver even more powerful, pertinent, and reliable studies to our valued clients in the pharmaceutical, biotech, and academic sectors.
We're excited to push the boundaries of neurodegenerative research further than ever before. Stay tuned for more updates as we embark on this thrilling new chapter!
EVENT Winner of Neuro-Sys' Ball Game, AAIC 24, Philadelphia
Congratulations to Sasha Milton from University of California, San Francisco, who scored Phillies vs. Yankees tickets as part of NEURO-SYS’ AAIC24 giveaway! We hope that he'll enjoy the game and have an unforgettable experience at Citizens Bank Park.
Special thanks to everyone who participated and helped make our giveaway a success.
EVENT June 3-6, 2024, San Diego, CA
Neuro-Sys will attend the Bio International Convention.
Our CEO, CSO and VP of Business Development invite you to the partnering meetings and explore collaborative opportunities with Neuro-Sys!
> More
EVENT May 21-23, 2024, Boston, MA
Neuro-Sys will sponsor and exhibit at the 3rd Annual ALS Drug Development Summit
> More
EVENT April 23-25, 2024, Boston, MA
Neuro-Sys will sponsor and exhibit at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
Our CSO will be giving a talk on: "Parkinson’s disease: alpha-synuclein’s mechanisms of cell death in vitro and in vivo evidences"
> More
INNOVATION January 18, 2024
CORTEX AI project
Thanks to the innovative integration of artificial intelligence into Neuro-Sys processes, CORTEX AI promises to revolutionize neuroscientific studies with unmatched precision, efficiency, and speed. This advanced technology enables complex data analysis for a better understanding of the mechanisms of action in neurodegenerative diseases, offering new perspectives and solutions in this critical field.
> More
